WO2007138328A3 - Novel applications for staphylococcus aureus sbi protein - Google Patents

Novel applications for staphylococcus aureus sbi protein Download PDF

Info

Publication number
WO2007138328A3
WO2007138328A3 PCT/GB2007/002022 GB2007002022W WO2007138328A3 WO 2007138328 A3 WO2007138328 A3 WO 2007138328A3 GB 2007002022 W GB2007002022 W GB 2007002022W WO 2007138328 A3 WO2007138328 A3 WO 2007138328A3
Authority
WO
WIPO (PCT)
Prior art keywords
staphylococcus aureus
complement
pathway
protein
novel applications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2007/002022
Other languages
French (fr)
Other versions
WO2007138328A2 (en
Inventor
Den Elsen Jean Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bath
Original Assignee
University of Bath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bath filed Critical University of Bath
Priority to AU2007266813A priority Critical patent/AU2007266813A1/en
Priority to CA002653668A priority patent/CA2653668A1/en
Priority to EP07733038A priority patent/EP2041165A2/en
Publication of WO2007138328A2 publication Critical patent/WO2007138328A2/en
Publication of WO2007138328A3 publication Critical patent/WO2007138328A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to the Sbi protein of Staphylococcus aureus. It has been found that Sbi can bind to the C3 complement protein and various proteolytic fragments thereof and consequently is able to inhibit the three complement pathways (i.e. the classical pathway, the alternative pathway and the lectin pathway). The invention therefore provides methods and compositions for inhibition of the complement system and for treatment of inflammatory conditions characterised by undesirable activation of the complement pathway.
PCT/GB2007/002022 2006-05-31 2007-05-31 Novel applications for staphylococcus aureus sbi protein Ceased WO2007138328A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2007266813A AU2007266813A1 (en) 2006-05-31 2007-05-31 Novel applications for Staphylococcus aureus Sbi protein
CA002653668A CA2653668A1 (en) 2006-05-31 2007-05-31 Novel applications for staphylococcus aureus sbi protein
EP07733038A EP2041165A2 (en) 2006-05-31 2007-05-31 Novel applications for staphylococcus aureus sbi protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0610776.7 2006-05-31
GB0610776A GB0610776D0 (en) 2006-05-31 2006-05-31 Novel applications for staphylococcus aureus Sbi protein

Publications (2)

Publication Number Publication Date
WO2007138328A2 WO2007138328A2 (en) 2007-12-06
WO2007138328A3 true WO2007138328A3 (en) 2008-05-08

Family

ID=36694713

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/002022 Ceased WO2007138328A2 (en) 2006-05-31 2007-05-31 Novel applications for staphylococcus aureus sbi protein

Country Status (5)

Country Link
EP (1) EP2041165A2 (en)
AU (1) AU2007266813A1 (en)
CA (1) CA2653668A1 (en)
GB (1) GB0610776D0 (en)
WO (1) WO2007138328A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008214359B2 (en) 2007-02-05 2014-01-16 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
US8592555B2 (en) 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
SG195555A1 (en) 2008-12-24 2013-12-30 Emd Millipore Corp Caustic stable chromatography ligands
GB201016403D0 (en) * 2010-09-29 2010-11-10 Bath Ventures Novel interaction between staphylococcus aureus Sbi and C3d protiens
WO2012095519A1 (en) * 2011-01-13 2012-07-19 Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie Potent inhibitors of complement activation
SG10201604559TA (en) * 2011-06-08 2016-07-28 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
WO2013142349A1 (en) * 2012-03-23 2013-09-26 University Of Chicago Compositions and methods related to staphylococcal sbi
GB201619965D0 (en) 2016-11-25 2017-01-11 Univ Of Bath The Immunogenic compositions comprising sbi protein and uses thereof
AU2022228575C1 (en) 2021-03-04 2025-10-09 Helix Nanotechnologies Inc Compositions including sbi adjuvants and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024467A1 (en) * 1997-11-12 1999-05-20 Biostapro Ab IgG-BINDING PROTEIN FROM STAPHYLOCOCCUS AND NUCLEOTIDE SEQUENCE ENCODING THIS PROTEIN
WO2002059148A2 (en) * 2001-01-26 2002-08-01 Intercell Ag A method for identification, isolation and production of antigens to a specific pathogen
WO2003011899A2 (en) * 2001-08-02 2003-02-13 University Of Sheffield Antigenic polypeptides
WO2006032472A2 (en) * 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Immunogenic composition for use in vaccination against staphylococcei
WO2007071692A2 (en) * 2005-12-21 2007-06-28 Glaxosmithkline Biologicals S.A. Immunogenic composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024467A1 (en) * 1997-11-12 1999-05-20 Biostapro Ab IgG-BINDING PROTEIN FROM STAPHYLOCOCCUS AND NUCLEOTIDE SEQUENCE ENCODING THIS PROTEIN
WO2002059148A2 (en) * 2001-01-26 2002-08-01 Intercell Ag A method for identification, isolation and production of antigens to a specific pathogen
WO2003011899A2 (en) * 2001-08-02 2003-02-13 University Of Sheffield Antigenic polypeptides
WO2006032472A2 (en) * 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Immunogenic composition for use in vaccination against staphylococcei
WO2007071692A2 (en) * 2005-12-21 2007-06-28 Glaxosmithkline Biologicals S.A. Immunogenic composition

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LEE LAWRENCE Y L ET AL: "Identification and characterization of the C3 binding domain of the Staphylococcus aureus extracellular fibrinogen-binding protein (Efb)", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 49, 3 December 2004 (2004-12-03), pages 50710 - 50716, XP002465564, ISSN: 0021-9258 *
SAHU A ET AL: "Structure and biology of complement protein C3, a connecting link between innate and acquired immunity", IMMUNOLOGICAL REVIEWS, MUNKSGAARD, vol. 180, April 2001 (2001-04-01), pages 35 - 48, XP002962792, ISSN: 0105-2896 *
WILLIAM T MORGAN: "Encyclopedia of Molecular Medicine, Volumes 1-5", 2002, JOHN WILEY & SONS, INC., XP002465565 *
ZHANG L ET AL: "A SECOND IGG-BINDING PROTEIN IN STAPHYLOCOCCUS AUREUS", MICROBIOLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 144, 1998, pages 985 - 991, XP001084184, ISSN: 1350-0872 *
ZHANG L ET AL: "Staphylococcus aureus expresses a cell surface protein that binds both IgG and beta2-glycoprotein I", MICROBIOLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 145, no. PART 1, January 1999 (1999-01-01), pages 177 - 183, XP002442501, ISSN: 1350-0872 *

Also Published As

Publication number Publication date
CA2653668A1 (en) 2007-12-06
EP2041165A2 (en) 2009-04-01
AU2007266813A1 (en) 2007-12-06
GB0610776D0 (en) 2006-07-12
WO2007138328A2 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
WO2008061724A3 (en) Compositions comprising carnosic acid 12-methylether
NO20084024L (en) Imidazole-based compounds, preparations comprising them, and their use
WO2008051416A3 (en) Compounds that inhibit the activity of hsp90 for treating infections
WO2010151799A3 (en) Compounds for modulating rna binding proteins and uses therefor
WO2010151797A3 (en) Compounds for modulating rna binding proteins and uses therefor
WO2008067219A3 (en) Quinazolinone modulators of tgr5
WO2009043889A3 (en) Oxadiazole derivatives
WO2007040650A3 (en) Apoptosis promoters
WO2006133396A3 (en) Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
MX2009000285A (en) Substituted piperidines that increase p53 activity and the uses thereof.
WO2008002571A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
EP2647692A3 (en) Compositions and methods comprising serine protease variants
WO2008060374A3 (en) Methods and compositions useful for diabetic wound healing
ATE495743T1 (en) TRIAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF DEGENERATIONAL AND INFLAMMATORY DISEASES
WO2008033562A3 (en) Kinase inhibitor compounds
MY157177A (en) Heteroaryl compounds useful as inhibitors of e1 activating enzymes
WO2007095601A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2009155001A3 (en) Wnt protein signalling inhibitors
WO2007059905A3 (en) Thienopyrimidines treating inflammatory diseases
WO2008133734A3 (en) Method and compositions for treating hiv infections
WO2008036379A3 (en) Serine hydrolase inhibitors
MA38296B2 (en) Selective nox-1 inhibitor peptides and their uses
WO2007009120A3 (en) Heterotetracyclic compounds as tpo mimetics
WO2007112121A3 (en) Tetracycline compounds and methods of treatment
WO2007109088A3 (en) Combinationtherapies of thiazolidinedione analogues and glucocorticoid agonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07733038

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2653668

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 573249

Country of ref document: NZ

Ref document number: 2007266813

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007733038

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007266813

Country of ref document: AU

Date of ref document: 20070531

Kind code of ref document: A